ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast
作者： Zheng Ping , Gene P. Siegal , Shuko Harada , Isam-Eldin Eltoum , Mariam Youssef
DOI: 10.18632/ONCOTARGET.13019
关键词:
摘要: // Zheng Ping 1 , Gene P. Siegal 1, 6 Shuko Harada Isam-Eldin Eltoum Mariam Youssef Tiansheng Shen Jianbo He 3 Yingjie Huang 7 Dongquan Chen 4, Yiping Li 2, Kirby I Bland 5, Helena R Chang 8 Dejun Division of Anatomic Pathology, University Alabama at Birmingham, AL, USA 2 Cell and Molecular Departments Hematology/Oncology, Department Medicine, 4 Preventive 5 Surgical Oncology, Surgery, UAB Comprehensive Cancer Center, Ningbo Clinical Pathological Diagnosis Ningbo, Zhejiang, China Revlon/UCLA Breast California Los Angeles, David Geffen School CA, Correspondence to: Shen, email: dshen@uabmc.edu Keywords: invasive lobular carcinoma, CDH1 mutation, ERBB2 genomics, TCGA Received: September 09, 2016 Accepted: October 24, Published: November 02, 2016 ABSTRACT E-cadherin ( ) is a glycoprotein that mediates adhesion between epithelial cells also suppresses cancer invasion. Mutation or deletion the gene has been reported in 30–60% cases carcinoma (ILC). However, little known about genomic differences ILC with without alteration. Therefore, we analyzed whole genome sequencing data 169 from The Genome Atlas (TCGA) to address this deficiency. Our study shows was altered 59.2% (100/169) ILC. No significant difference identified -altered -unaltered for any examined demographic, clinical pathologic characteristics, including histologic grade, tumor stage, lymph node metastases, ER/PR/HER2 states. Seven recurrent mutations PTEN MUC16 FAT4 PCDHGA2 HERC1 FLNC four chromosomal changes copy number variation (CNV) (11q13, 17q12-21, 8p11 8q11) were found ILC, which correlated positive negative alteration status, respectively. prevalence most common breast driver abnormalities TP53 PIK3CA MYC amplifications showed no two groups. an mutation significantly worse prognosis compared its counterparts such mutation. suggests patients may represent actionable group who could benefit targeted therapy.
impactjournals.com参考文章(23)
Sunil R Lakhani, Ian O Ellis, Stuart Schnitt, Puay Hoon Tan, Marc van de Vijver, WHO classification of tumours of the breast International Agency for Research on Cancer. ,(2012)
Giovanni Ciriello, Michael L Gatza, Andrew H Beck, Matthew D Wilkerson, Suhn K Rhie, Alessandro Pastore, Hailei Zhang, Michael McLellan, Christina Yau, Cyriac Kandoth, Reanne Bowlby, Hui Shen, Sikander Hayat, Robert Fieldhouse, Susan C Lester, MK Gary, Rachel E Factor, Laura C Collins, Kimberly H Allison, Yunn-Yi Chen, Kristin Jensen, Nicole B Johnson, Steffi Oesterreich, Gordon B Mills, Andrew D Cherniack, Gordon Robertson, Christopher Benz, Chris Sander, Peter W Laird, Katherine A Hoadley, Tari A King, Rehan Akbani, J Todd Auman, Miruna Balasundaram, Saianand Balu, Thomas Barr, Andrew Beck, Stephen Benz, Mario Berrios, Rameen Beroukhim, Tom Bodenheimer, Lori Boice, Moiz S Bootwalla, Jay Bowen, Denise Brooks, Lynda Chin, Juok Cho, Sudha Chudamani, Tanja Davidsen, John A Demchok, Jennifer B Dennison, Li Ding, Ina Felau, Martin L Ferguson, Scott Frazer, Stacey B Gabriel, JianJiong Gao, Julie M Gastier-Foster, Nils Gehlenborg, Mark Gerken, Gad Getz, William J Gibson, D Neil Hayes, David I Heiman, Andrea Holbrook, Robert A Holt, Alan P Hoyle, Hai Hu, Mei Huang, Carolyn M Hutter, E Shelley Hwang, Stuart R Jefferys, Steven JM Jones, Zhenlin Ju, Jaegil Kim, Phillip H Lai, Michael S Lawrence, Kristen M Leraas, Tara M Lichtenberg, Pei Lin, Shiyun Ling, Jia Liu, Wenbin Liu, Laxmi Lolla, Yiling Lu, Yussanne Ma, Dennis T Maglinte, Elaine Mardis, Jeffrey Marks, Marco A Marra, Cynthia McAllister, Shaowu Meng, Matthew Meyerson, Richard A Moore, Lisle E Mose, Andrew J Mungall, Bradley A Murray, Rashi Naresh, Michael S Noble, Olufunmilayo Olopade, Joel S Parker, Charles M Perou, Todd Pihl, Gordon Saksena, Steven E Schumacher, Kenna R Mills Shaw, Nilsa C Ramirez, W Kimryn Rathmell, Jeffrey Roach, A Gordon Robertson, Jacqueline E Schein, Nikolaus Schultz, Margi Sheth, Yan Shi, Juliann Shih, Carl Simon Shelley, Craig Shriver, Janae V Simons, Heidi J Sofia, Matthew G Soloway, Carrie Sougnez, Charlie Sun, Roy Tarnuzzer, Daniel G Tiezzi, David J Van Den Berg, Doug Voet, Yunhu Wan, Zhining Wang, John N Weinstein, Daniel J Weisenberger, Richard Wilson, Lisa Wise, Maciej Wiznerowicz, Junyuan Wu, Ye Wu, Liming Yang, Travis I Zack, Jean C Zenklusen, Jiashan Zhang, Erik Zmuda, None, Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell. ,vol. 163, pp. 506- 519 ,(2015) , 10.1016/J.CELL.2015.09.033
Monica Iorfida, Eugenio Maiorano, Enrico Orvieto, Patrick Maisonneuve, Luca Bottiglieri, Nicole Rotmensz, Emilia Montagna, Silvia Dellapasqua, Paolo Veronesi, Viviana Galimberti, Alberto Luini, Aron Goldhirsch, Marco Colleoni, Giuseppe Viale, Invasive lobular breast cancer: subtypes and outcome Breast Cancer Research and Treatment. ,vol. 133, pp. 713- 723 ,(2012) , 10.1007/S10549-012-2002-Z
Haixin Lei, Sara Sjöberg-Margolin, Sima Salahshor, Barbro Werelius, Eva Jandáková, Kari Hemminki, Annika Lindblom, Igor Vořechovský, CDH1 mutations are present in both ductal and lobular breast cancer, but promoter allelic variants show no detectable breast cancer risk. International Journal of Cancer. ,vol. 98, pp. 199- 204 ,(2002) , 10.1002/IJC.10176
Huang-Chun Lien, Yu-Ling Chen, Yu-Lin Juang, Yung-Ming Jeng, Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast Breast Cancer Research and Treatment. ,vol. 150, pp. 447- 455 ,(2015) , 10.1007/S10549-015-3336-0
David J. Dabbs, Stuart J. Schnitt, Felipe C. Geyer, Britta Weigelt, Frederick L. Baehner, Thomas Decker, Vincenzo Eusebi, Stephen B. Fox, Shu Ichihara, Sunil R. Lakhani, Jose Palacios, Emad Rakha, Andrea L. Richardson, Fernando C. Schmitt, Puay-Hoon Tan, Gary M. Tse, Anne Vincent-Salomon, Ian O. Ellis, Sunil Badve, Jorge S. Reis-Filho, Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. The American Journal of Surgical Pathology. ,vol. 37, pp. 1- 11 ,(2013) , 10.1097/PAS.0B013E3182918A2B
Dejun Shen, Zheng Ping, JonasS Almeida, GeneP Siegal, StuartJ Schnitt, Mining genome sequencing data to identify the genomic features linked to breast cancer histopathology Journal of Pathology Informatics. ,vol. 5, pp. 3- 3 ,(2014) , 10.4103/2153-3539.126147
Emad A. Rakha, Arjun Patel, Des G. Powe, Ahmed Benhasouna, Andrew R. Green, Maryou B. Lambros, Jorge S. Reis-Filho, Ian O. Ellis, Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. The American Journal of Surgical Pathology. ,vol. 34, pp. 1472- 1479 ,(2010) , 10.1097/PAS.0B013E3181F01916
Ron Bose, Shyam M. Kavuri, Adam C. Searleman, Wei Shen, Dong Shen, Daniel C. Koboldt, John Monsey, Nicholas Goel, Adam B. Aronson, Shunqiang Li, Cynthia X. Ma, Li Ding, Elaine R. Mardis, Matthew J. Ellis, Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer Cancer Discovery. ,vol. 3, pp. 224- 237 ,(2013) , 10.1158/2159-8290.CD-12-0349
Noa Efrat Ben-Baruch, Ron Bose, Shyam M. Kavuri, Cynthia X. Ma, Matthew J. Ellis, HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor Journal of The National Comprehensive Cancer Network. ,vol. 13, pp. 1061- 1064 ,(2015) , 10.6004/JNCCN.2015.0131